Bristol-Myers Signs $15.2B Strategic Oncology Pact in China
Deal valued at $15.2 billion covers rights to three immuno-oncology candidates in China with a $2.5 billion upfront payment and potential $12.7 billion in regulatory and sales milestones, granting exclusive commercialization through 2042. Partnership with Shanghai-based Innovent Biologics includes joint development funding and co-promotion across 3,000 hospitals.
1. Deal Structure
Bristol-Myers granted exclusive Greater China rights to three immuno-oncology candidates under a joint-venture model with Shanghai-based Innovent Biologics, covering mainland China, Hong Kong, Macau and Taiwan. The agreement includes co-promotion in over 3,000 hospitals and shared regulatory filings to streamline approvals.
2. Financial Terms
The deal comprises a $2.5 billion upfront cash payment, plus up to $12.7 billion in milestone payments tied to clinical, regulatory and sales targets by year-end 2042. Profit splits on net sales will follow a tiered structure favoring the first-to-market candidate.
3. Strategic Impact
This marks Bristol-Myers’s largest China licensing transaction, bolstering its oncology portfolio in the world’s second-largest pharmaceutical market. It accelerates local footprint expansion and leverages Innovent’s established commercialization network to drive mid- to high-single-digit revenue growth by 2028.
4. Next Steps
Regulatory submissions for the lead candidate are slated for H2 2026 with potential approval by 2027, followed by launches of the two follow-on therapies in 2028–29. Joint steering committees will oversee development milestones and marketing roll-outs across major urban centers.